Half-Year 2022 Financial and Clinical Trials Update

Pharma Division CER sales growth¹ in % Global top 20 products Roche Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Ocrevus 16 31 7 25 18 17 Perjeta 2 7 2 3 1 9 Hemlibra 33 58 37 38 30 31 Tecentriq 26 31 23 17 8 13 Actemra/RoActemra 22 12 57 21 3 -23 Herceptin -35 -35 -26 -6 -19 -11 Avastin -40 -40 -37 -30 -32 -27 MabThera -46 -34 -42 -26 -21 -20 Kadcyla 17 21 11 16 9 18 Xolair -6 3 8 14 9 13 Alecensa 14 25 18 15 23 16 Ronapreve 272 -91 Lucentis -7 TNKase/Activase -17 23 2 -10 2 -26 -9 3 3 -20 1 Evrysdi Esbriet -8 Gazyva -2 18 10 ܂ Phesgo Pulmozyme CellCept -23 -5 जेजे -13 -3 * 50 * 7 M 347 མ་རྩ་ 189 65 -5 -7 -6 -21 10 10 7 9 -7 3 -2 * 52 410 168 -3 2 -12 -3 CER = Constant Exchange Rates; * over 500%; 1Q1-Q4/21 vs Q1-Q4/20; Q1-Q2/22 vs Q1-Q2/21 167

View entire presentation